Correction: NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation., (Cell Cycle, (2019), 12, 24, (3817-3823), 10.4161/cc.26672);NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation

Cell Cycle

Volumn 12, Issue 24, 2013, Pages 3817-3823

  Salah, Zaidoun ^a,b   Cohen, Sherri ^a   Itzhaki, Ella ^a   Aqeilan, Rami I ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b AL QUDS UNIVERSITY   (Palestine)

Author keywords

Hippo pathway; LATS1; NEDD4; Protein protein interaction; WW domain

Indexed keywords

LATS1 PROTEIN; PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; EMBRYO; HIPPO SIGNALING PATHWAY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UBIQUITINATION;

HIPPO PATHWAY; LATS1; NEDD4; PROTEIN-PROTEIN INTERACTION; WW DOMAIN;

CELL NUCLEUS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HEK293 CELLS; HUMANS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROLINE; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84891706068     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2019.1607022     Document Type: Erratum

References (37)

1. Schroeder MC, Halder G. Regulation of the Hippo pathway by cell architecture and mechanical signals. Semin Cell Dev Biol 2012; 23:803-11; PMID:22750148; http://dx.doi.org/10.1016/j.semcdb.2012.06.001
2. Artemenko Y, Devreotes PN. Hippo on the move: tumor suppressor regulates adhesion and migration. Cell Cycle 2013; 12:535-6; PMID:23370390; http://dx.doi.org/10.4161/cc.23668
3. Bao Y, Hata Y, Ikeda M, Withanage K. Mammalian Hippo pathway: from development to cancer and beyond. J Biochem 2011; 149:361-79; PMID:21324984; http://dx.doi.org/10.1093/jb/mvr021
4. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24:862-74; PMID:20439427; http://dx.doi.org/10.1101/gad.1909210
5. Liu AM, Wong KF, Jiang X, Qiao Y, Luk JM. Regulators of mammalian Hippo pathway in cancer. Biochim Biophys Acta 2012; 1826:357-64; PMID:22683405
6. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel.2010.09.011
7. Sudol M, Harvey KF. Modularity in the Hippo signaling pathway. Trends Biochem Sci 2010; 35:627-33; PMID:20598891; http://dx.doi.org/10.1016/j.tibs. 2010.05.010
8. Salah Z, Aqeilan RI. WW domain interactions regulate the Hippo tumor suppressor pathway. Cell Death Dis 2011; 2:e172; PMID:21677687; http://dx.doi.org/10.1038/cddis.2011.53
9. Visser S, Yang X. LATS tumor suppressor: a new governor of cellular homeostasis. Cell Cycle 2010; 9:3892-903; PMID:20935475; http://dx.doi.org/10. 4161/cc.9.19.13386
10. Xia H, Qi H, Li Y, Pei J, Barton J, Blackstad M, Xu T, Tao W. LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 2002; 21:1233-41; PMID:11850843; http://dx.doi.org/10.1038/sj.onc.1205174
11. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124:1169-81; PMID:16564011; http://dx.doi.org/10.1016/j.cell.2006.02.037
12. Hisaoka M, Tanaka A, Hashimoto H. Molecular alterations of h-warts/LATS1 tumor suppressor in human soft tissue sarcoma. Lab Invest 2002; 82:1427-35; PMID:12379777; http://dx.doi.org/10.1097/01.LAB.0000032381.68634.CA
13. Chakraborty S, Khare S, Dorairaj SK, Prabhakaran VC, Prakash DR, Kumar A. Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis. Genomics 2007; 90:344-53; PMID:17604597; http://dx.doi.org/10.1016/j.ygeno.2007.05.002
14. Fernandez-L A, Kenney AM. The Hippo in the room: a new look at a key pathway in cell growth and transformation. Cell Cycle 2010; 9:2292-9; PMID:20581446; http://dx.doi.org/10.4161/cc.9.12.11919
15. Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009; 28:521-7; PMID:19937137; http://dx.doi.org/10.1007/s10059-009-0158-0
16. Yeung B, Ho KC, Yang X. WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS One 2013; 8:e61027; PMID:23573293; http://dx.doi.org/10.1371/journal.pone.0061027
17. Ho KC, Zhou Z, She YM, Chun A, Cyr TD, Yang X. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. [corrected]. Proc Natl Acad Sci U S A 2011; 108:4870-5; PMID:21383157; http://dx.doi.org/10.1073/pnas. 1101273108
18. Salah Z, Melino G, Aqeilan RI. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res 2011; 71:2010-20; PMID:21212414; http://dx.doi.org/10.1158/0008-5472.CAN-10-3516
19. Chen C, Matesic LE. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev 2007; 26:587-604; PMID:17726579; http://dx.doi.org/10.1007/s10555-007-9091-x
20. Harvey KF, Kumar S. Nedd4-like proteins: an emerging family of ubiquitin-protein ligases implicated in diverse cellular functions. Trends Cell Biol 1999; 9:166-9; PMID:10322449; http://dx.doi.org/10.1016/S0962-8924(99) 01541-X
21. Yang B, Kumar S. Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ 2010; 17:68-77; PMID:19557014; http://dx.doi.org/10.1038/cdd.2009.84
22. Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, Stambolic V, Rotin D. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A 2008; 105:8585-90; PMID:18562292; http://dx.doi.org/10.1073/pnas.0803233105
23. Kim SS, Yoo NJ, Jeong EG, Kim MS, Lee SH. Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS 2008; 116:779-84; PMID:19024597; http://dx.doi.org/10.1111/j.1600-0463.2008.00999.x
24. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A, Srivastava S. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem 2008; 283:28988-95; PMID:18703514; http://dx.doi.org/10.1074/jbc.M710528200
25. Fouladkou F, Lu C, Jiang C, Zhou L, She Y, Walls JR, Kawabe H, Brose N, Henkelman RM, Huang A, et al. The ubiquitin ligase Nedd4-1 is required for heart development and is a suppressor of thrombospondin-1. J Biol Chem 2010; 285:6770-80; PMID:20026598; http://dx.doi.org/10.1074/jbc.M109.082347
26. Murdaca J, Treins C, Monthouël-Kartmann MN, Pontier-Bres R, Kumar S, Van Obberghen E, Giorgetti-Peraldi S. Grb10 prevents Nedd4-mediated vascular endothelial growth factor receptor-2 degradation. J Biol Chem 2004; 279:26754-61; PMID:15060076; http://dx.doi.org/10.1074/jbc.M311802200
27. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, Trapasso F, Han SY, Melino G, Huebner K, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci U S A 2004; 101:4401-6; PMID:15070730; http://dx.doi.org/10.1073/pnas.0400805101
28. Del Mare S, Salah Z, Aqeilan RI. WWOX: its genomics, partners, and functions. J Cell Biochem 2009; 108:737-45; PMID:19708029; http://dx.doi.org/10. 1002/jcb.22298
29. Yu FX, Mo JS, Guan KL. Upstream regulators of the Hippo pathway. Cell Cycle 2012; 11:4097-8; PMID:23075495; http://dx.doi.org/10.4161/cc.22322
30. Liu CY, Lv X, Li T, Xu Y, Zhou X, Zhao S, Xiong Y, Lei QY, Guan KL. PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. J Biol Chem 2011; 286:5558-66; PMID:21189257; http://dx.doi.org/10.1074/jbc.M110.194019
31. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25:51-63; PMID:21205866; http://dx.doi.org/10.1101/gad.2000111
32. Chan SW, Lim CJ, Huang C, Chong YF, Gunaratne HJ, Hogue KA, Blackstock WP, Harvey KF, Hong W. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2011; 30:600-10; PMID:20972459; http://dx.doi.org/10.1038/onc.2010.438
33. Xiao L, Chen Y, Ji M, Dong J. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J Biol Chem 2011; 286:7788-96; PMID:21233212; http://dx.doi.org/10.1074/jbc.M110.173468
34. Cao XR, Lill NL, Boase N, Shi PP, Croucher DR, Shan H, Qu J, Sweezer EM, Place T, Kirby PA, et al. Nedd4 controls animal growth by regulating IGF-1 signaling. Sci Signal 2008; 1:ra5; PMID:18812566; http://dx.doi.org/10.1126/ scisignal.1160940
35. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283:5496-509; PMID:18158288; http://dx.doi.org/10.1074/jbc.M709037200
36. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M, Croce CM. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 2005; 65:6764-72; PMID:16061658; http://dx.doi.org/10.1158/0008-5472.CAN-05-1150
37. Salah Z, Aqeilan R, Huebner K. WWOX gene and gene product: tumor suppression through specific protein interactions. Future Oncol 2010; 6:249-59; PMID:20146584; http://dx.doi.org/10.2217/fon.09.152